Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE19.4800
- TODAY'S CHANGE (%)-0.1000 (-0.5107%)
- Bid / Lots19.2500/ 2
- Ask / Lots20.1400/ 1
- Open / Previous Close19.7700 / 19.5800
- Day Range
- 52 Week Range
- Volume205,113
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 4221 | 19.73 |
| 09:34 ET | 1375 | 19.77 |
| 09:36 ET | 722 | 19.7882 |
| 09:38 ET | 100 | 19.775 |
| 09:39 ET | 330 | 19.8 |
| 09:43 ET | 907 | 19.78 |
| 09:45 ET | 843 | 19.66 |
| 09:50 ET | 500 | 19.67 |
| 09:56 ET | 433 | 19.71 |
| 09:57 ET | 122 | 19.73 |
| 10:01 ET | 921 | 19.71 |
| 10:03 ET | 139 | 19.675 |
| 10:12 ET | 100 | 19.6484 |
| 10:19 ET | 650 | 19.64 |
| 10:21 ET | 100 | 19.6 |
| 10:28 ET | 100 | 19.63 |
| 10:30 ET | 200 | 19.615 |
| 10:32 ET | 301 | 19.63 |
| 10:33 ET | 100 | 19.61 |
| 10:35 ET | 1500 | 19.62 |
| 10:37 ET | 100 | 19.635 |
| 10:39 ET | 557 | 19.58 |
| 10:42 ET | 526 | 19.59 |
| 10:44 ET | 1100 | 19.7 |
| 10:46 ET | 600 | 19.685 |
| 10:48 ET | 300 | 19.6648 |
| 10:50 ET | 8468 | 19.79 |
| 10:55 ET | 127 | 19.77 |
| 10:57 ET | 523 | 19.76 |
| 11:00 ET | 1539 | 19.7001 |
| 11:02 ET | 500 | 19.7 |
| 11:08 ET | 292 | 19.69 |
| 11:11 ET | 119 | 19.64 |
| 11:15 ET | 500 | 19.62 |
| 11:18 ET | 561 | 19.65 |
| 11:22 ET | 100 | 19.655 |
| 11:33 ET | 100 | 19.63 |
| 11:38 ET | 100 | 19.63 |
| 11:42 ET | 707 | 19.62 |
| 11:44 ET | 805 | 19.68 |
| 11:47 ET | 200 | 19.665 |
| 11:51 ET | 100 | 19.67 |
| 11:54 ET | 1299 | 19.63 |
| 11:56 ET | 300 | 19.63 |
| 12:02 ET | 114 | 19.6 |
| 12:03 ET | 100 | 19.61 |
| 12:07 ET | 679 | 19.59 |
| 12:09 ET | 332 | 19.58 |
| 12:12 ET | 200 | 19.61 |
| 12:14 ET | 798 | 19.6 |
| 12:23 ET | 2141 | 19.61 |
| 12:25 ET | 1075 | 19.61 |
| 12:27 ET | 100 | 19.6 |
| 12:30 ET | 300 | 19.59 |
| 12:32 ET | 202 | 19.57 |
| 12:39 ET | 100 | 19.5625 |
| 12:41 ET | 100 | 19.565 |
| 12:45 ET | 127 | 19.57 |
| 12:48 ET | 1702 | 19.625 |
| 12:50 ET | 200 | 19.625 |
| 12:57 ET | 879 | 19.61 |
| 01:03 ET | 2016 | 19.58 |
| 01:06 ET | 216 | 19.555 |
| 01:08 ET | 100 | 19.54 |
| 01:12 ET | 323 | 19.54 |
| 01:14 ET | 314 | 19.55 |
| 01:15 ET | 436 | 19.55 |
| 01:32 ET | 221 | 19.555 |
| 01:37 ET | 627 | 19.56 |
| 01:39 ET | 747 | 19.53 |
| 01:53 ET | 667 | 19.49 |
| 02:04 ET | 833 | 19.53 |
| 02:08 ET | 300 | 19.55 |
| 02:09 ET | 100 | 19.55 |
| 02:11 ET | 224 | 19.55 |
| 02:13 ET | 500 | 19.57 |
| 02:15 ET | 227 | 19.575 |
| 02:18 ET | 941 | 19.52 |
| 02:20 ET | 100 | 19.5 |
| 02:22 ET | 100 | 19.5 |
| 02:24 ET | 1105 | 19.4912 |
| 02:26 ET | 462 | 19.5 |
| 02:27 ET | 100 | 19.49 |
| 02:29 ET | 200 | 19.495 |
| 02:33 ET | 1438 | 19.46 |
| 02:38 ET | 600 | 19.45 |
| 02:40 ET | 100 | 19.445 |
| 02:42 ET | 144 | 19.46 |
| 02:45 ET | 200 | 19.47 |
| 02:51 ET | 936 | 19.47 |
| 02:54 ET | 100 | 19.48 |
| 03:03 ET | 100 | 19.46 |
| 03:05 ET | 1301 | 19.43 |
| 03:07 ET | 2127 | 19.43 |
| 03:09 ET | 400 | 19.422 |
| 03:14 ET | 206 | 19.43 |
| 03:16 ET | 219 | 19.44 |
| 03:20 ET | 308 | 19.46 |
| 03:21 ET | 200 | 19.46 |
| 03:25 ET | 110 | 19.47 |
| 03:27 ET | 200 | 19.45 |
| 03:30 ET | 200 | 19.44 |
| 03:32 ET | 600 | 19.45 |
| 03:34 ET | 5760 | 19.42 |
| 03:36 ET | 516 | 19.44 |
| 03:38 ET | 700 | 19.43 |
| 03:39 ET | 3442 | 19.41 |
| 03:41 ET | 831 | 19.42 |
| 03:43 ET | 400 | 19.39 |
| 03:45 ET | 749 | 19.4 |
| 03:48 ET | 900 | 19.42 |
| 03:50 ET | 200 | 19.42 |
| 03:52 ET | 2502 | 19.45 |
| 03:54 ET | 1427 | 19.46 |
| 03:56 ET | 1532 | 19.44 |
| 03:57 ET | 1212 | 19.44 |
| 03:59 ET | 41651 | 19.48 |
May 7, 2024
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
May 3, 2024
DJ Kiniksa Pharmaceuticals Initiated at Overweight by Wells Fargo, from 11:59AM ET on Friday May 03, 2024 by Dow Jones
11:59AM ET on Friday May 03, 2024 by Dow Jones
May 1, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan, from 10:58AM ET on Wednesday May 01, 2024 by Dow Jones
10:58AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 24, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 23, 2024
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution, from 7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 228.6x | --- |
Dynavax Technologies Corp | 1.4B | 220.2x | --- |
MiMedx Group Inc | 1.2B | 20.9x | --- |
Ginkgo Bioworks Holdings Inc | 1.9B | -2.0x | --- |
BioCryst Pharmaceuticals Inc | 1.2B | -5.0x | --- |
MannKind Corp | 1.2B | 192.1x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President and Chief Commercial Officer
- Ross Moat
- Senior Vice President and Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 228.6x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 127.9x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
